Bladder Cancer Therapeutics Market – Global Industry Insights,
Trends, Outlook, and Opportunity Analysis, 2018–2026
As per stats released by the World Cancer Research Fund International, around 430,000 new cases
of bladder cancer were diagnosed in 2012, with bladder cancer being the ninth-most common
cancer. The bladder holds urine before it leaves the body during urination. The disease in which
cancerous cells form in the tissues of the bladder is known as bladder cancer. There are three major
types of bladder cancer and are named on the basis of type of cells become cancerous (malignant).
These type are as follows –
•Transitional Cell Carcinoma: Transitional cell carcinoma is also called as urothelial
carcinoma. It begins in the urothelial cells of the bladder which are located in the lining the
bladder. This is the common type of bladder cancer.
•Squamous Cell Carcinoma: This type of cancer initiates in the squamous cells and it
develops in the bladder, following prolonged irritation or infection
•Adenocarcinoma: This type of cancer begins in the secretory cells (glandular) that are
located in the lining of bladder. This is very rare type of bladder cancer.
According to the study of American Society of Clinical Oncology (ASCO), urothelial carcinoma
accounts for around 90%, squamous cell carcinoma accounts 4% and adenocarcinoma accounts 2%
of all bladder cancer. The remaining 4% bladder cancer includes other rare type of bladder cancer
viz. sarcoma and small cell anaplastic cancer.